Domainex is hosting a team meeting in Basel for the EFM Medical Chemistry conference in 2026
Public source
Publisher name
Public post
Meet the team if you are in Basel this week for #EFMCMedicinalChemistry2026
Company
Domainex
Driving Discovery - Delivering Leads
- Industry
- Biotechnology Research
- Location
- Saffron Walden, GB
- Company size
- 51–200 employees
About Domainex
Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years. Domainex’s highly experienced molecular, protein, structural and assay biologists plus medicinal, computational and analytical chemists can be leveraged through our CRO services. Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets. Domainex offers a range of services including: • Medicinal chemistry (including SBDD) • FragmentBuilder (Domainex’s proprietary fragment screening platform) • Computational Chemistry (including LeadBuilder Domainex’s proprietary virtual screening platform) • Assay Development and Screening (biochemical, biophysical and cell assays) • iPSC and immune cell biology • Protein Production • CDH (Domainex’s proprietary technology which enables the rapid identification of stable, soluble protein domains) • Analytical chemistry • X-ray crystallography services Whether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing prudent management of your own budget.
See moreLatest activity
Latest activity from Domainex
17 signals
Presence & Recognition
Domainex is collaborating with One Nucleus for an upcoming webinar introducing Domainex's next-generation polymer nanodisc platform PureDisc.
Presence & Recognition
Domainex is exhibiting at the EFMC European Federation for Medicinal Chemistry and Chemical Biology session at poster #216, outlining its membrane protein production platform enabled by PureDisc technology and benefits of biophysics screening and CryoEM structure improvements.
Presence & Recognition
Domainex participated in Day 2 of the European Federation for Medicinal Chemistry and Chemical Biology conference in Basel.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
HitGen Inc.
HitGen Inc. and Vernalis teams will be sharing how DEL, FBDD/SBDD, protein and structural sciences, and integrated chemistry and biology can work together to identify, validate and advance novel chemical starting points at the EFMC2026 conference in Basel from September 6 to 10.
Presence & Recognition
Amphista Therapeutics Limited
Amphista Therapeutics Limited is attending the EFMC International Symposium on Medicinal Chemistry 2026 in Basel.
Presence & Recognition
IRBM
IRBM is attending the EFMC International Symposium on Medicinal Chemistry in Basel, France, from September 8 to September 11, 2026.
Presence & Recognition
Sygnature Discovery
Sygnature Discovery announced that registration for the conference on fragment-based drug discovery closes on the 7th September.
Presence & Recognition
Eurofins Discovery